Trial Profile

Freiburg ZNS-NHL study: Therapy for patients with primary non-Hodgkin lymphoma of the CNS [central nervous system]-sequential high dosage chemotherapy with autologous peripheral blood stem cell transplantation.

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 28 May 2019

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Carmustine (Primary) ; Cytarabine (Primary) ; Rituximab (Primary) ; Thiotepa (Primary) ; Methotrexate
Indications Non-Hodgkin's lymphoma
Focus Therapeutic Use

06 Dec 2016 Results presented at the 58th Annual Meeting and Exposition of the American Society of Hematology.
02 Mar 2013 New source identified and integrated (European Clinical Trials Database: EudraCT2005-000615-99).
06 Jun 2012 New source identified and integrated (German Clinical Trials Register; DRKS00003748).

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com